コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 hibitor voxilaprevir (sofosbuvir-velpatasvir-voxilaprevir).
2 ciated with treatment regimens that included voxilaprevir.
3 onstructural protein 3/4A protease inhibitor voxilaprevir.
4 ported more frequently by patients receiving voxilaprevir.
5 receiving 8 weeks of sofosbuvir-velpatasvir-voxilaprevir.
6 itor velpatasvir, and the protease inhibitor voxilaprevir (150 patients) or matching placebo (150 pat
7 1:1 ratio to receive sofosbuvir-velpatasvir-voxilaprevir (163 patients) or sofosbuvir-velpatasvir (1
8 I], 86-100) receiving sofosbuvir-velpatasvir-voxilaprevir alone and 24 of 25 (96%; 95% CI, 80-100) re
9 nly reported AEs with sofosbuvir-velpatasvir-voxilaprevir alone were diarrhea and bronchitis; and wit
12 domly to groups given sofosbuvir-velpatasvir-voxilaprevir for 8 weeks or sofosbuvir-velpatasvir for 1
13 id not establish that sofosbuvir-velpatasvir-voxilaprevir for 8 weeks was noninferior to sofosbuvir-v
16 bronchitis; and with sofosbuvir-velpatasvir-voxilaprevir plus RBV were fatigue, anemia, gastroenteri
17 ration (FDA) approved sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) (Vosevi) fixed-dose combinati
20 patients discontinued sofosbuvir-velpatasvir-voxilaprevir therapy because of an adverse event (AE).
21 an SVR to 8 weeks of sofosbuvir-velpatasvir-voxilaprevir; this did not meet the criterion to establi
22 riority of 8 weeks of sofosbuvir-velpatasvir-voxilaprevir to 12 weeks of sofosbuvir-velpatasvir using
23 d-dose combination of sofosbuvir-velpatasvir-voxilaprevir was well tolerated and effective at achievi
24 combination tablet of sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin (RBV) for 12 week
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。